Apogee Therapeutics (APGE) Interest Expenses (2026)

Apogee Therapeutics (APGE) has reported Interest Expenses for 5 consecutive years, with $268.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 681450.39% year-over-year to $268.2 million; the TTM figure through Mar 2026 stood at $268.2 million (up 681450.39% YoY), while the FY2025 annual figure was $216.2 million, up 184.12% from the prior year.
• Interest Expenses grew to $268.2 million in Q1 2026 per APGE's latest filing, from $216.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $268.2 million in Q1 2026 and bottomed at $39345.0 in Q1 2025.
• Historically, Interest Expenses has averaged $68.0 million across 5 years, with a median of $37.1 million in 2023.
• Annual changes were most pronounced in 2025 — Interest Expenses plunged 99.97% — and 2026, when it jumped 681450.39%.
• Apogee Therapeutics' Interest Expenses stood at $6.7 million in 2022, then jumped by 351.56% to $30.2 million in 2023, then jumped by 152.11% to $76.1 million in 2024, then soared by 184.12% to $216.2 million in 2025, then grew by 24.05% to $268.2 million in 2026.
• Business Quant data shows APGE's Interest Expenses at $268.2 million in Q1 2026, $216.2 million in Q4 2025, and $43.9 million in Q3 2025.